A、C、Y 和 W-135 群脑膜炎球菌结合疫苗。
Meningococcal group A, C, Y and W-135 conjugate vaccine.
机构信息
Infectious Diseases Epidemiology Research Unit, University of Pittsburgh Graduate School of Public Health and School of Medicine, Pittsburgh, Pennsylvania 15101, USA.
出版信息
Nat Rev Drug Discov. 2010 Jun;9(6):429-30. doi: 10.1038/nrd3194.
DOI:10.1038/nrd3194
PMID:20514064
Abstract
In February 2010, a quadrivalent conjugate vaccine (Menveo; Novartis Vaccines and Diagnostics) was approved by the US FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 in people aged 11-55 years.
摘要
2010 年 2 月，美国食品药品监督管理局批准了一种四价结合疫苗（Menveo；诺华疫苗和诊断公司），用于预防侵袭性脑膜炎奈瑟菌血清群 A、C、Y 和 W-135 引起的 11-55 岁人群的疾病。
Zotero 插件